Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-02-01
1998-04-14
Achutamurthy, Ponnathapura
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 514 21, 425 851, 425 852, A61K 3807, A61K 3800
Patent
active
057391106
ABSTRACT:
A method of promoting regeneration of hemopoietic cells in a subject undergoing chemotherapy or radiotherapy, which method includes the steps of (i) administering to the subject a first amount of AcSDKP or an agonist thereof, the first amount being effective to reduce the proliferation of hemopoietic cells during the chemotherapy or radiotherapy; (ii) administering to the subject a second amount of an angiotensin-converting enzyme (ACE) inhibitor, said second amount being effective to reduce the degradation of said AcSDKP or an agonist thereof by angiotensin-converting enzyme; and (iii) after the chemotherapy or radiotherapy, administering to the subject a second amount of a hemopoiesis growth factor, the second amount being effective to stimulate the proliferation of hemopoietic cells.
REFERENCES:
patent: 5114926 (1992-05-01), Frindel et al.
Rieger et al., "Involvement of Human Plasma Angiotensin I-converting Enzyme in the Degradation of the Haemoregulatory . . . ", Biochem. J., pp. 1-6, 1993.
Rousseau et al., "The Hemoregulatory Peptide N-Acetyl-Ser-Asp-Lys-Pro Is a Natural and Specific Substrate of the N-terminal . . . ", The Journal of Biological Chemistry, 270:3656-3661, 1995.
Aline Masse, "Rapport Du Congres International D'Expression Francaise Organise Par Biomatec", a Marrakech du 26 au 31 mars 1995.
Castelli et al., "Protective, Restorative, and Therapeutic Properties of Recombinant Human IL-1 in Rodent Models", The Journal of Immunology 140:3830-3837, 1988.
Fibbe et al., "A Single Low Dose of Human Recombinant Interleukin 1 Accelerates the Recovery of Neutrophils in Mice with Cyclophosphamide-induced Neutropenia", Experimental Hematology 17:805-808, 1989.
Futami et al., "Chemoprotective Effects of Recombinant Human IL-1.alpha. In Cyclophosphamide-Treated Normal and Tumor-Bearing Mice", The Journal of Immunology 145:4121-4130, 1990.
Gianni et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Reduces Hematologic Toxicity and Widens Clinical Applicability of . . . ", Journal of Clinical Oncology 8:768-778, 1990.
Guigon et al., "A Convenient Source of CFU-s Inhibitors: The Fetal Calf Liver", Cell Tissue Kinet 17:49-55, 1984.
Guigon et al., "Effects of CFU-S Inhibitors On Murine Bone Marrow During ARA-C Treatment--I. Effects On Stem Cells", Leukemia Research 4:385-391, 1980.
Lenfant et al., "Inhibitor or Hematopoietic Pluripotent Stem Cell Proliferation: Purification and Determination of its Structure", Proc. Natl. Acad. Sci. USA 86:779-782, 1989.
Moore et al., "Synergy of Interleukin 1 and Granulocyte colony-Stimulating Factor: In vivo Stimulation of Stem-Cell Recovery and Hematopoietic Regeneration . . . ", Proc. Natl. Acad. Sci. USA 84:7134-7138, 1987.
Neta et al., "Interleukin 1 is a Radioprotector", The Journal of Immunology 136;2483-2485, 1986.
Oppenheim et al., "Interleukin-1 Enhances Survival of Lethally Irradiated Mice Treated With Allogeneic Bone Marrow Cells", Blood 74:2257-2263, 1989.
Schuening et al., "Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Hematopoiesis of Normal Dogs & on Hematopoietic Recovery After Otherwise Lethal Total Body . . . ", Blood 74:1308-1313, 1989.
Steward et al., "Clinical Applications of Myeloid Colony Stimulating Factors", Cancer Treatment Reviews 17:77-87, 1990.
Tanikawa et al., "Effects of Recombinant Granulocyte Colony-Stimulating Factor (rG-CSF) and Recombinant Granulocyte-Macrophage Colony-Stimulating . . . ", Exp. Hemotol 17:883-888, 1989.
Thierry et al., Synthesis and Activity of NAcSerAspLysPro Analogues on Cellular Interactions Between T-Cell and Erythrocytes in Rosette Formation, J. Med. Chem. 33:2122-2127, 1990.
Till et al., "A Direct Measurement of the Radiation Sensitivity of Normal Mouse Bone Marrow Cells", Radiation Research 14:213-222, 1961.
Tubiana et al., "Ways of Minimizing Hematopoietic Damage Induced by Radiation and Cytostatic Drugs--The Possible Role of Inhibitors", Radiotherapy and Oncology 29:1-17, 1993.
Wdzieczak-Bakala et al., "Further Purification of a CFU-S Inhibitor: In Vivo Effects After Cytosine Arabinoside Treatment", Biomedicine & Pharmacotherapy 37:467-471, 1983.
Welte et al., "Recombinant Human Granulocyte Colony-Stimulating Factor . . . ", J. Exp. Med. 165:941-948, 1987.
Robinson et al., "The Molecular Specificity of Action of the Tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the Control of Hematopoietic Stem Cell Proliferation", Stem Cells 11:422-427, 1993.
Paukovits et al., "Pre-CFU-S Quiescence and Stem Cell Exhaustion After Cytostatic Drug Treatment: Protective Effects of the Inhibitory Peptide pGlu-Glu-Asp-Cys-Lys (pEEDCK)", Blood 81:1755-1761, 1993.
Bogden Arthur E.
De Paillette Evelyn Deschamps
Achutamurthy Ponnathapura
Biomeasure Inc.
Conway John D.
Societe de Conseils de Recherches Et D'Applications Scientifique
LandOfFree
Protection of hemopoietic cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection of hemopoietic cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of hemopoietic cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-634613